- Home
- JAZZ
as 03-25-2025 12:34pm EST
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
| Founded: | 2003 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN |
| Market Cap: | 8.4B | IPO Year: | 2007 |
| Target Price: | $187.15 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 8.65 | EPS Growth: | 41.75 |
| 52 Week Low/High: | $99.06 - $148.06 | Next Earning Date: | 04-30-2025 |
| Revenue: | $4,068,950,000 | Revenue Growth: | 6.12% |
| Revenue Growth (this year): | 7.3% | Revenue Growth (next year): | 4.01% |
Stock Insider Trading Activity of Jazz Pharmaceuticals plc (Ireland) (JAZZ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Iannone Robert | JAZZ | EVP, Global Head of R&D & CMO | Mar 10 '25 | Sell | $138.41 | 2,403 | $332,604.52 | 79,621 | |
| Carr Patricia | JAZZ | SVP, Chief Accounting Officer | Mar 7 '25 | Sell | $137.81 | 1,140 | $157,103.40 | 7,012 | |
| Iannone Robert | JAZZ | EVP, Global Head of R&D & CMO | Mar 5 '25 | Sell | $139.11 | 7,080 | $981,297.72 | 79,621 | |
| Patil Neena M | JAZZ | EVP & Chief Legal Officer | Feb 27 '25 | Sell | $144.87 | 3,800 | $550,506.00 | 33,318 | |
| COZADD BRUCE C | JAZZ | Chairman & CEO | Feb 27 '25 | Sell | $144.25 | 6,500 | $937,625.00 | 464,058 | |
| Carr Patricia | JAZZ | SVP, Chief Accounting Officer | Feb 27 '25 | Sell | $144.04 | 5,586 | $805,842.21 | 7,012 | |
| COZADD BRUCE C | JAZZ | Chairman & CEO | Feb 3 '25 | Sell | $122.31 | 1,500 | $183,465.00 | 464,058 | |
| COZADD BRUCE C | JAZZ | Chairman & CEO | Jan 2 '25 | Sell | $123.43 | 1,500 | $185,145.00 | 464,058 |
Latest Jazz Pharmaceuticals plc (Ireland) News
JAZZ Breaking Stock News: Dive into JAZZ Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term
Zacks
2 days ago
Zacks.com featured highlights include MPLX LP, Leidos, Jazz Pharmaceuticals, Fortinet and Pilgrim's Pride
TipRanks
4 days ago
TPB, ACB and JAZZ: Three Pot Stocks Flowering With Potential Upside
Zacks
5 days ago
5 High ROE Stocks to Buy as Markets Dip Despite Rate Cut Hopes
Zacks
7 days ago
Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect?
StockStory
7 days ago
3 Value Stocks Skating on Thin Ice
PR Newswire
7 days ago
Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting
Investor's Business Daily
9 days ago
Cash In On The Luck Of The Irish With 5 St. Patrick's Day Stocks Near Buy Points
Compare JAZZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JAZZ Jazz Pharmaceuticals plc (Ireland) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.